INDUSTRIAL NEWS

IVD NEWS of Vazyme Biotech and Amoy Diagnostics

Release Time:2020/12/28 Click:

Vazyme's IPO was accepted, planning to raise 1.225 billion yuan!

 1.png

On December 24, 2020, the Shanghai Stock Exchange successfully accepted the listing application of Vazyme Biotech Co.,Ltd, and planned to raise RMB 1.225 billion.

 

From 2017 to the first half of 2020, the total operating income of Vazyme Biotech was RMB 112,372,300, RMB 170,804,700, RMB 268,380,100, and RMB 793,460,500. The net profit attributable to shareholders of the parent company was RMB 3.6446 million and RMB 1.0387 million, respectively. The gross profit margin of the main business was 86.38%, 84.78%, 84.78% and 93.51%, respectively.

 

Vazyme Biotech Co.,Ltd. was set up in 2016, which is a high-tech private enterprises, focusing on the in vitro diagnostic products, the research and development, production, sales and service of equipment, products cover heart head blood-vessel, infection,eugenics, tumor, renal function,  children's respiratory tract and other fields, is one of the most comprehensive enterprise of domestic POCT product line. Vazyme Biotech Co.,Ltd. was successfully selected into the list of "potential enterprises of Forbes unlisted companies" and the first group of "unicorns" and "gazelle enterprises" cultivated in Nanjing at 2018.

 

Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China

 2.jpg

Amoy Diagnostics announced recently that it has signed an agreement with Merck KGaA to develop a companion diagnostic test in China to support Merck KGaA's novel MET inhibitor tepotinib (Tepmetko).


Amoy PCR-11 gene product is an upgraded version of PCR-9 gene product, which can provide clinical testing of core tumor driver genes including MET gene.In the performance study organized by the National Cancer Center of Japan, the product has been unanimously recognized by mainstream clinical institutions in Japan for its excellent performance, simple and quick clinical application experience, and is the next ROS1 companion product included in the Japanese and Korean medical insurance.With this cooperation, Amoy PCR-11 gene product has become the world's first companion diagnostic product for oral MET inhibitor Tepotinib approved for marketing in Japan and China, highlighting Amoy's position and brand influence in the field of tumor companion diagnosis at home and abroad.

Copyright © 2018 CACLP